FDA's Pharmacy Compounding Advisory Committee (PCAC) is meeting July 23-24, 2026 to vote on whether seven peptides should be recommended for the Section 503A Bulks List: BPC-157, KPV, TB-500 and MOTS-c on day one, then emideltide (delta sleep-inducing peptide, or DSIP), Semax and Epitalon on day two. It is the most consequential public proceeding on these compounds in years, and it has produced a wave of "peptides are legal in 2026" content that misstates what a vote does.
This piece explains what is actually on the table. Three things are worth holding onto before the headlines land. FDA's own review staff recommended against adding all seven. The committee's vote is advisory and does not change the law on the day it is cast. And the April 2026 removal of these peptides from FDA's Category 2 list, which many outlets reported as legalization, did not make any of them legal to compound.
As of publication on July 23, no vote tallies had been publicly reported. This piece covers what is confirmed on the record and will be updated when FDA publishes meeting minutes.
What PCAC is voting on, and what it is not
Section 503A of the Food, Drug, and Cosmetic Act lets a state-licensed pharmacy compound a drug from a bulk drug substance only under one of three conditions: the substance has a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA's published 503A Bulks List, codified at 21 CFR 216.23. None of the seven peptides meets any of those conditions today. The Bulks List pathway is the only realistic one, and getting onto it is what this meeting is about.
PCAC is an advisory committee. It hears presentations from nominators and FDA reviewers, then votes on a recommendation. FDA is not bound by the result. As the law firm Orrick put it in its pre-meeting client alert, even if PCAC recommends inclusion, FDA must still decide whether to accept that recommendation before publishing a notice of proposed rulemaking, and the formal rulemaking process cannot be bypassed entirely.
So the vote is a gate, not a finish line. A "yes" opens the door to a rulemaking process. A "no" closes it, at least for this round.
FDA staff recommended against all seven
This is the detail most consumer coverage has skipped. FDA's briefing materials for the meeting reached the same conclusion for every one of the seven substances: do not add them to the 503A Bulks List.
The recurring objections in the agency's review were inadequate physicochemical characterization of the substances, insufficient or entirely absent human clinical trial evidence, and specific safety flags. Among the seven, KPV, TB-500 and MOTS-c were assessed as having no human clinical data at all. FDA also cited immunogenicity concerns, adverse event reports for BPC-157 in the FAERS database, and the World Anti-Doping Agency's prohibited status for TB-500 and MOTS-c.
Advisory committees do sometimes vote against agency staff, and this committee faces unusual political attention given the administration's public support for broader peptide access. But a reader trying to calibrate expectations should know that the agency's own scientific reviewers entered the room recommending rejection across the board. PeptaHub takes no position on whether the underlying evidence is adequate; that judgment belongs to the committee and, ultimately, to FDA.
The April Category 2 removal was not legalization
On April 15, 2026, FDA announced it would remove 12 peptides from Category 2 of its nominated-bulk-substances review, effective within seven calendar days. Category 2 is the bucket for substances FDA has flagged as raising significant safety risks. The 12 included BPC-157, cathelicidin LL-37, dihexa acetate, emideltide, Epitalon, injectable GHK-Cu, KPV, pegylated mechano growth factor, melanotan II, MOTS-c, Semax, and thymosin beta-4 (marketed as TB-500).
The stated reason for removal was procedural: the original nominations had been withdrawn by the nominators. That is a docket housekeeping action, not a safety finding in the peptides' favor.
Both Orrick and Frier Levitt published client alerts making the same point in near-identical terms. Orrick wrote that removal from Category 2 does not, by itself, place these substances on the 503A Bulks List or into Category 1, for which FDA exercises enforcement discretion, and advised that stakeholders should not begin compounding with any of the 12 peptides solely on the basis of their removal. Frier Levitt wrote that removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A.
The practical effect is that these peptides moved out of an explicit "do not compound" designation into an unresolved status, without gaining permission. Anyone who read April's headlines as a green light read them wrong.
The 12-to-24 month reality after a favorable vote
Suppose the committee votes yes on one or more peptides and FDA accepts the recommendation. What follows is standard administrative rulemaking: a notice of proposed rulemaking, a public comment period typically running 60 to 90 days, agency review of the comments, and then a final rule adding the substance to 21 CFR 216.23. Orrick's estimate for that full sequence is 12 to 24 months, with the caveat that the administration may try to accelerate it but cannot skip the statutory steps.
That timeline starts after the vote and after FDA decides to act on it. Neither of those has happened yet for any peptide on the list. A reader who wants a concrete answer to "when could my pharmacy legally compound this" should be looking at 2027 or 2028 in the most favorable scenario, and at "not at all" in the scenario FDA staff recommended.
Separately, a final rule would still have to resolve questions no public document has answered: permissible dosage forms and concentrations, whether a substance is added for 503A only or also for 503B outsourcing facilities, and which indications are in scope. USP monograph development, which sets the analytical standards compounders must meet for identity, purity and potency, typically lags regulatory permission by a further stretch.
What actually changes for consumers right now
Nothing, in the near term. On July 25, 2026, the legal status of BPC-157 or TB-500 will be exactly what it was on July 22. A vote is a recommendation about a future rule.
This matters because the vote is already being used as a marketing event. Products sold today as "research peptides," or offered outside a licensed 503A pharmacy operating against a patient-specific prescription, are not legally compounded under any pathway, and a favorable advisory vote will not retroactively make them so. Marketing that treats the July meeting as the moment of legalization is describing something that did not happen.
It is also worth separating these seven from FDA-approved prescription peptides. Semaglutide and tirzepatide are approved drugs with their own distinct regulatory and compounding history. Their status is not affected by this proceeding, and the two categories should not be reasoned about together.
What to watch next
Four documents carry the actual signal, in order of when they should appear. First, the PCAC vote tallies for each substance, which FDA typically summarizes shortly after the meeting and formalizes in published minutes. Second, FDA's response to the recommendations, which is a separate decision and may take months. Third, a notice of proposed rulemaking in the Federal Register citing 21 CFR 216.23 for any specific substance, which is the first document that represents real legal movement. Fourth, the second PCAC meeting covering LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF, expected to be scheduled before the end of February 2027.
The public docket for this proceeding is FDA-2025-N-6895. Our regulatory timeline tracks each of these milestones as they publish, and our peptide legal-status guide covers the 503A and 503B framework in more depth.
One closing note on how to read the coverage this week. A committee vote, an FDA decision, a proposed rule and a final rule are four different events, and only the last one changes what a pharmacy may lawfully do. Headlines will tend to collapse them. The distinction is the whole story.